Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DY0D | ISIN: US1508376076 | Ticker-Symbol: LSRM
Tradegate
20.11.24
20:35 Uhr
0,580 Euro
-0,011
-1,78 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CEL-SCI CORPORATION Chart 1 Jahr
5-Tage-Chart
CEL-SCI CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
0,5620,59020:27
0,5650,58820:03

Aktuelle News zur CEL-SCI Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.11.CEL SCI CORP - 8-K, Current Report9
07.11.CEL-SCI, FDA agree on Phase 3 trial design for cancer drug7
07.11.FDA agrees with CEL-SCI's patient selection for cancer study7
25.10.CEL-SCI files to sell 1M shares of common stock for holders12
29.09.CEL-SCI Aktie: Biotechfirma vor Quartalsbericht unter Druck736Die CEL-SCI Corporation, ein Biotechnologieunternehmen im klinischen Stadium, steht vor wichtigen Entwicklungen. Der Aktienkurs des Unternehmens, das sich auf Immuntherapien gegen Krebs und andere Krankheiten...
► Artikel lesen
16.09.CEL-SCI Corporation: CEL-SCI's Multikine Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation3925-year survival rate of 82.6% and 73% reduction in overall risk of death (hazard ratio of 0.27) are the strongest Multikine efficacy results reported to date, reflecting results in patients who...
► Artikel lesen
CEL-SCI Aktie jetzt für 0€ handeln
10.09.CEL-SCI Corporation: CEL-SCI to Present New Data for Multikine Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress309Data to be presented on Saturday, September 14 and published via a press release before the open of market on Monday, September 16 CEL-SCI Corporation (NYSE American: CVM) today reported it...
► Artikel lesen
04.09.CEL-SCI gains UK pediatric waiver for cancer treatment2
04.09.Original-Research: CEL-SCI Corporation (von First Berlin Equity Research GmbH): Buy - Kursziel: USD6.20268Original-Research: CEL-SCI Corporation - from First Berlin Equity Research GmbH 04.09.2024 / 12:31 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The...
► Artikel lesen
30.08.CEL SCI CORP - S-8, Securities to be offered to employees in employee benefit plans2
15.08.Cel-Sci GAAP EPS of -$0.42 misses by $0.315
15.08.CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results179VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2024, as well as key recent clinical and corporate developments. Clinical...
► Artikel lesen
26.07.CEL SCI CORP - 8-K, Current Report9
26.07.XFRA LSRM: WIEDERAUFNAHME/RESUMPTION310FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
26.07.XFRA LSRM: AUSSETZUNG/SUSPENSION334DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCEL-SCI CORP. NEW...
► Artikel lesen
26.07.CEL-SCI stock rallies 40% on Multikine study analysis results13
26.07.CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results212VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported positive results from a bias analysis conducted for its concluded Phase 3 study of Multikine (Leukocyte Interleukin...
► Artikel lesen
08.07.CEL-SCI names Robert Watson as chair5
18.06.CEL-SCI Corporation: CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population307Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors 73% survival for Multikine vs...
► Artikel lesen
11.06.Original-Research: CEL-SCI Corporation (von First Berlin Equity Research GmbH): Buy - Kursziel: USD6.20321Original-Research: CEL-SCI Corporation - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to CEL-SCI Corporation Company Name: CEL-SCI Corporation ISIN:...
► Artikel lesen
Seite:  Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1